Overview

The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt.

Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score.

Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.

Eligibility

Inclusion Criteria:

• All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography

Exclusion Criteria:

• Patients with a history of significant alcohol consumption more than 30 g/day in men and > 20 g/day in women.
• Patients with positive hepatitis B or C virus markers.
• Patients with autoimmune hepatitis.
• Patients with any other metabolic liver disease.
• Patients with hepatic focal lesions.